Found 68 clinical trials
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An observational study
-
For all genders
-
Hematology
-
Currently Recruiting
Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study
The purpose of this study is to evaluate the safety and efficacy of apixaban for the prevention of thromboembolism in adult patients with congenital heart disease (CHD) and non-valvular atrial
- 2 views
- 03 Feb, 2021
- 8 locations
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An observational study
-
For all genders
-
Neurology
-
Currently Recruiting
Monitoring of NOAC Therapy: Standardizing Reference Intervals
This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and rivaroxaban) in ethnic Chinese patients.
- 0 views
- 26 Jan, 2021
- 1 location
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An observational study
-
For all genders
-
Currently Recruiting
Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients
Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.
- 39 views
- 22 Feb, 2021
- 2 locations
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An observational study
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study
persons. This study try to better define wether the pharmacology of each of these 3 drugs (dabigatran, rivaroxaban and apixaban) is actually significantly different in very older patients (over 80) and to
- 6 views
- 23 Jan, 2021
- 4 locations
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An observational study
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Oral Anti-coagulants in Fragile Patients With Percutaneous Endoscopic Gastrostomy and Atrial Fibrillation (ORIGAMI) Pilot Study
bioavailability for apixaban, rivaroxaban, and edoxaban". However, at the moment, there are no evidences supporting unequivocally the use of DOAC via PEG. The purpose of this study is to evaluate the
- 6 views
- 26 Jan, 2021
- 1 location
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An observational study
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
DOAC in Unusual Site Venous Thrombosis
-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators
- 0 views
- 25 Jan, 2021
- 1 location
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An observational study
-
For all genders
-
Currently Recruiting
Registry of Patient With Antithrombotic Agents Admitted to an Emergency Department
(Apixaban rivaroxaban, dabigatran ...) should profoundly change the management of venous thromboembolism and cardioembolic event. Because of their risk-benefit, simplicity and convenience of their
- 0 views
- 21 Jan, 2021
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An observational study
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
'Understanding the Electrophysiological Substrate Underlying Persistent Atrial Fibrillation Study II (USURP AF- Study II)'
Atrial fibrillation (AF) is the most common type of chronic heart rhythm disease worldwide, with significant associated co-morbidities. Although there have been advances in understanding the mechanisms of AF, the underlying cause of AF and factors which perpetuate it remain incompletely understood. This is particularly the case for persistent AF …
- 1 views
- 23 Jan, 2021
- 1 location